Revenue
2022
2023
2024
Rua Life Sciences plc (RUA)
Price£0.2800Cached quote
Financial statements
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Revenue | £2.2M | £2.2M | £1.6M |
| Research & development | £873,000 | £1.1M | £911,000 |
| Operating expenses | £3.7M | £4.1M | £3.7M |
| Operating income | −£2.0M | −£2.3M | −£2.3M |
| Operating margin | −89.14% | −106.06% | −144.55% |
| EBITDA | −£1.6M | −£2.0M | −£2.0M |
| EBITDA margin | −72.52% | −89.63% | −125.29% |
| Net income | −£1.4M | −£2.0M | −£2.1M |
| Net profit margin | −65.72% | −91.92% | −127.20% |
| Basic EPSper basic share | -£0.04 | -£0.09 | -£0.09 |
| Diluted EPSper diluted share | -£0.04 | -£0.09 | -£0.09 |
Owners
Reported major voting-rights holders
4.95%of voting rights
Dowgate Group LimitedNotified Jun 1, 2026
View holders
| Holder | Voting rights |
|---|---|
| 4.95%Jun 1, 2026 · 3.07M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: FCA voting-rights notice ↗Updated Oct 21, 2026